Peritoneal dialysis in patients with refractory congestive heart failure: Potential prognostic factors

Blood Purification

Volumn 35, Issue 4, 2013, Pages 285-294

  Kunin, Margarita ^a   Arad, Michael ^b   Dinour, Dganit ^a   Freimark, Dov ^b   Holtzman, Eli J ^a  

^a Nephrology and Hypertension Institute   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cardiorenal syndrome; Congestive heart failure; Peritoneal dialysis; Peritoneal ultrafiltration

Indexed keywords

DIURETIC AGENT; SERUM ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; INOTROPIC AGENT; METOLAZONE; SODIUM; VASOACTIVE AGENT; VASODILATOR AGENT; VASOCONSTRICTOR AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE MASS; HOSPITALIZATION; HUMAN; MALE; OBSERVATIONAL STUDY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROGNOSIS; SODIUM BLOOD LEVEL; SURVIVAL RATE; TREATMENT OUTCOME; ULTRAFILTRATION; HUMAN CELL; LEUKOCYTE COUNT; LONG TERM SURVIVAL; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; REFRACTORY CONGESTIVE HEART FAILURE; SURVIVOR; BLOOD; DISEASE FREE SURVIVAL; DRUG EFFECTS; FOLLOW UP; HEART FAILURE; MORTALITY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

AGED; DISEASE-FREE SURVIVAL; DIURETICS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; PERITONEAL DIALYSIS; RETROSPECTIVE STUDIES; SODIUM; SURVIVAL RATE; VASOCONSTRICTOR AGENTS;

EID: 84878068524     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000351202     Document Type: Article

References (40)

1. American Heart Association: Heart Disease and Stroke Statistics: 2006 Update. Dallas, American Heart Association 2006.
2. Pang PS, Komajda M, Gheorghiade M: The current and future management of acute heart failure syndromes. Eur Heart J 2010; 31: 784-793.
3. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D: Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107-115.
4. Jessup M, Brozena S: Heart failure. N Engl J Med 2003; 348: 2007-2018.
5. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM: Renal impairment and outcomes in heart failure: systematic review and metaanalysis. J Am Coll Cardiol 2006; 47: 1987-1996.
6. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J, ADHERE Scientific Advisory Committee and Investigators: High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007; 13: 422-430.
7. Khalifeh N, Vychytil A, Ho WH: The role of peritoneal dialysis in the management of treatment- resistant congestive heart failure: a European perspective. Kidney Int Suppl 2006; 103:S72-S75.
8. Krishnan A, Oreopoulos DG: Peritoneal dialysis in congestive heart failure. Adv Perit Dial 2007; 23: 82-89.
9. Kazory A, Ross EA: Contemporary trends in the pharmacological and extracorporeal management of heart failure. A nephrologic perspective. Circulation 2008; 117: 975-983.
10. Gotloib L, Fudin R, Yakubovich M, Vienken J: Peritoneal dialysis in refractory end-stage congestive heart failure: a challenge fading a no-win situation. Nephrol Dial Transplant 2005; 20(suppl 7):32-36.
11. Zoccali C, Enia G, Tripepi G, Panuccio V, Mallamaci F: Clinical epidemiology of major nontraditional risk factors in peritoneal dialysis patients. Perit Dial Int 2005; 25(suppl 3):S84-S87.
12. Van Biesen W, Verbeke F, Vanholder R: Ca rdiovascular disease in haemodialysis and peritoneal dialysis: arguments pro peritoneal dialysis. Nephrol Dial Transplant 2007; 22: 53-58.
13. Mehrotra R, Khanna R: Peritoneal ultrafiltration for chronic congestive heart failure: rationale, evidence and future. Cardiology 2001; 96: 177-182.
14. Mehrotra R, Kathuria P: Place of peritoneal dialysis in the management of treatment-resistant congestive heart failure. Kidney Int 2006: 70; 67-71.
15. Sanchez JE, Ortega T, Rodriguez C, Diaz-Molina B, Martin M, Garcia-Cueto C, Vidau P, Gago E, Ortega F: Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure. Nephrol Dial Transplant 2010; 25: 605-610.
16. Sotirakopoulos NG, Kalogiannidou IM, Tersi ME, Mavromatidis KS: Peritoneal dialysis for patients suffering from severe heart failure. Clin Nephrol 2011; 76: 124-129.
17. Cnossen TT, Kooman JP, Konings CJAM, Uszko-Lencer NHMK, Leunissen KML, van der Sande FM: Peritoneal dialysis in patients with primary cardiac failure complicated by renal failure. Blood Purif 2010; 30: 146-152.
18. Koch M, Haastert B, Kohnle M, Rump LC, Kelm M, Trapp R, Aker S: Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory. heart failure and chronic kidney disease. Eur J Heart Fail 2012; 14: 530-539.
19. Hebert MJ, Falardeau M, Pichette V, Houde M, Nolin L, Cardinal J, Ouimet D: Continuous ambulatory peritoneal dialysis for patients with severe left ventricular systolic dysfunction and end-stage renal disease. Am J Kidney Dis 1995; 25: 761-768.
20. Mousson C, Tanter Y, Chalopin JM, Rebibou JM, Dentam G, Morelon P, Rifle G: Treatment of refractory congestive cardiac insufficiency by continuous peritoneal dialysis. Long-term course. Presse Med 1988; 17: 1617-1620.
21. Ryckelynck JP, Lobbedez T, Valette B, Le Goff C, Mazouz O, Levaltier B, Potier JC, Hurault de Ligny B: Peritoneal ultrafiltration and refractory congestive heart failure. Adv Perit Dial 1997; 13: 93-97.
22. Elhalel-Dranitzki M, Rubinger D, Moscovici A, Haviv YS, Friedlaender MM, Silver J, Popovtzer MM: CAPD to improve quality of life in patients with refractory heart failure. Nephrol Dial Transplant 1998; 13: 3041-3042.
23. Lee WH, Packer M: Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986; 73: 257-267.
24. Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC: Albumin levels predict survival in patients with systolic heart failure. Am Heart J 2008; 155: 883-889.
25. Cooper HA, Exner DV, Waclawiw MA, Domaski MJ: White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies Of Left Ventricular Dysfunction [SOLVD]). Am J Cardiol 1999; 84: 252-257.
26. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007; 116: 1482-1487.
27. Hillege HL, Girbes ARJ, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-210.
28. Quinones MA, Greenberg BH, Kopelen HA, Koilpillai C, Limacher MC, Shindler DM, Shelton BJ, Weiner DH: Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 2000; 35: 1237-1244.
29. Narang R, Cleland JG, Erhardt L, Ball SG, Coats AJ, Cowley AJ, Dargie HJ, Hall AS, Hampton JR, Poole-Wilson PA: Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 1996; 17: 1390-403.
30. Mouton CP, Bazaldua OV, Pierce B, Espino DV: Common infections in older adults. Am Fam Physician 2001; 63: 257-268.
31. Lee DS, Gona P, Albano I, Larson MG, Benjamin EJ, Levy D, Kannel WB, Vasan RS: A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction. Circ Heart Fail 2011; 4: 36-43.
32. Ryckelynck JP, Lobbedez T, Valette B, Le Goff C, Mazouz O, Levaltier B, Potier JC, Hurault de Ligny B: Peritoneal ultrafiltration and treatment-resistant heart failure. Nephrol Dial Transplant 1998; 13(suppl 4):56-59.
33. Wang Q, Bernardini J, Piraino B, Fried L: Albumin at the start of peritoneal dialysis predicts the development of peritonitis. Am J Kidney Dis 2003; 41: 664-669.
34. Yang CY, Chen TW, Lin YP, Lin CC, Ng YY, Yang WC, Chen JY: Determinants of catheter loss following continuous ambulatory peritoneal dialysis peritonitis. Perit Dial Int 2008; 28: 361-370.
35. Pajek J, Gucek A, Škoberne A, Pintar T: Severe peritonitis in patients treated with peritoneal dialysis: a case series study. Ther Apher Dial 2011; 15: 250-256.
36. Blake PG, Flowerdew G, Blake RM, Oreopoulos DG: Serum albumin in patients on continuous ambulatory peritoneal dialysis-predictors and correlations with outcomes. J Am Soc Nephrol 1993; 3: 1501-1507.
37. Artero A, Zaragoza R, Camarena JJ, Sancho S, Gonzalez R, Nogueira JM: Prognostic factors of mortality in patients with community-acquired bloodstream infection with severe sepsis and septic shock. J Crit Care 2010; 25: 276-281.
38. Churchill DN, Taylor DW, Cook RJ, LaPlante P, Barre P, Carter P, Fay WP, Goldstein MB, Jindal K, Mandin H: Canadian hemodialysis morbidity study. Am J Kidney Dis 1992; 19: 214-234.
39. Powe NR, Jaar B, Furth SL, Hermann J, Briggs W: Septicemia in dialysis patients: incidence, risk factors, and prognosis. Kidney Int 1999; 55: 1081-1090.
40. Kaysen GA: The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 2001; 12: 1549-1557.